Public

Health

Statement


logo_udal_300px

The Morris K. Udall Center of Excellence for Parkinson’s Disease Research at The Feinstein Institute for Medical Research employs rigorously validated Parkinson’s disease- (PD-) related networks to address vital issues that impact heavily on the care of today’s PD patients. Because dopaminergic treatment is generally so effective for the motor symptoms of PD, at least early on, it is easy to dismiss the very real problems that ultimately develop: levodopa-induced dyskinesias and cognitive and behavioral changes for some patients. Understanding these phenomena should not only help us improve the lives of patients, but will provide unique insight into the pathophysiology of PD and perhaps other neurodegenerative disorders. Likewise, the validation of an automated pattern-based method for early diagnosis will help streamline trials of new therapies for PD as well as for atypical parkinsonian syndromes.



Project 1
Microvascular Changes in Parkinson’s Disease:
Relationship to Levodopa-Induced Dyskinesia (LID)

Investigating How Blood Flow in the Brain
Is Altered by LID

Project 2
Metabolic Networks and the Cognitive Treatment Response
in Parkinson’s Disease

Tracking the Effects of Drug Therapy on Learning, Decision-making,
and the Cognition-related Metabolic Network in the Brain

Project 3
Early Differential Diagnosis of Parkinsonism
with Metabolic Imaging and Pattern Analysis

Distinguishing PD from other Neurodegenerative Diseases